## IN BRIEF

### New Adult Immunization Recommendations

The 2017 adult immunization schedule approved by the CDC's Advisory Committee on Immunization Practices (ACIP) includes some new or revised recommendations. The complete schedule is available on the CDC’s website (www.cdc.gov/vaccines/schedules). New recommendations for use of influenza vaccine during the 2016-2017 season were included in a previous issue of *The Medical Letter*. Updated recommendations for other vaccines are summarized below. Recommendations for routine use of vaccines in adults were reviewed in an earlier issue.

### Human Papillomavirus Vaccine (HPV: Gardasil, Gardasil 9)

**Update:** Dosing schedules for young adults who did not complete an HPV vaccine series as adolescents

- Previously unvaccinated adult females ≤26 years old and males ≤21 years old who have immunocompromising conditions (including HIV infection) and those who have sex with men should also receive a 3-dose series. All of those above who received 2 doses ≥5 months apart before age 15 do not need an additional dose. All of those above who received only 1 dose or 2 doses <5 months apart before age 15 should receive 1 additional dose.

**Hepatitis B Vaccine**

**Update:** List of chronic liver disease conditions for which Hep B vaccine is recommended

- Adults with chronic liver disease including, but not limited to, hepatitis C virus infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, and an ALT or AST level >2 times the upper limit of normal should receive a 3-dose series (0, 1, and 6 months).

**Meningococcal Conjugate Vaccine Serogroups A, C, W, and Y (MenACWY: Menactra, Menveo)**

**Update:** MenACWY vaccine is recommended for all adults with HIV infection

- Previously unvaccinated adults with HIV infection should receive 2 doses ≥2 months apart and should be revaccinated every 5 years.
- Adults with HIV infection who previously received 1 dose should receive a second dose ≥2 months after the first.

**Meningococcal Vaccine Serogroup B (MenB-FHbp: Trumenba; MenB-4C: Bexsero)**

**Update:** Dosing schedule for Trumenba

- Adults who are at increased risk for meningococcal disease (anatomical or functional asplenia, persistent complement component deficiencies, microbiologists routinely exposed to isolates of Neisseria meningitidis) and those who are vaccinated during serogroup B disease outbreaks should receive a 3-dose series (0, 1-2, and 6 months) of Trumenba. (2 doses of Bexsero ≥1 month apart can be given instead.)
- Young adults 16 through 23 years old who are healthy and not at increased risk for meningococcal disease may receive a 2-dose series (0 and 6 months) of Trumenba. (2 doses of Bexsero ≥1 month apart may be given instead.)